The appearance of left ventricular hypertrophy on 12-lead electrocardiography (ECG-LVH) has been clarified to be associated with the risk of incidence of cardiovascular events (CVEs) in hypertensive individuals and the general population, but not enough in non-hypertensive individuals.
Left ventricular hypertrophy (LVH) has been acknowledged as a cardiac end-organ response to increased pressure or volume load and a key example of target organ damage due to hypertension. 1 For the diagnosis of LVH, 12-lead electrocardiography (ECG) has been widely used as a simple and inexpensive tool in the clinical setting. In addition, the appearance of LVH on ECG has been shown to be associated with the incidence of cardiovascular events (CVEs) in hypertensive individuals 2, 3 or a general population including hypertensive individuals. [4] [5] [6] Hypertension is a major risk factor of CVE; however, not a few CVEs occur in individuals with no hypertension, as more than 50% of patients with coronary heart disease did not have a history of hypertension in international clinical trials. 7 Further, in individuals with no hypertension, LVH has been reported to be indicated by alterations in blood glucose and lipid metabolism which are cardiovascular risk factors, 8, 9 and be at the high risk of future incidence of hypertension. 10, 11 These evidence have prompted the hypothesis that ECG-LVH is a predictive marker for incident CVE in a non-hypertensive population; however, this has not yet been clarified. The identification of individuals at the high risk for future CVE by using ECG would worth considering to enable interventions to be targeted with greater accuracy among large numbers of non-hypertensive individuals.
This study thus was conducted to examine the utility of ECG-LVH on the prediction of incident CVE for non-hypertensive individuals in a Japanese community-based sample.
METHODS

Study participants
The Iwate-KENCO study cohort is a population-based prospective study conducted for residents in northern Iwate prefecture, in the northeast area of Honshu, Japan. Details of this cohort have been provided elsewhere. 12 Participants were recruited from a government-regulated health checkup program conducted between April 2002 and January 2005. Of the study participants for which the ECG data were completely recorded (n = 8,685), a total of 3,647 participants were excluded from the analysis for the following reasons: <40 years of age (n = 360), hypertension (defined as systolic blood pressure (BP) ≥140 mm Hg, diastolic BP ≥90 mm Hg, and/or the current use of antihypertensive agents, n = 2,986), prevalent CVE (myocardial infarction or stroke; n = 282), missing readable ECGs (n = 239) or missing covariates (n = 47). In addition, 92 participants with WolffParkinson-White pattern, paced rhythm, complete left or right bundle branch block, or atrial fibrillation/flutter were excluded. Ultimately, 4,946 participants (1,789 males and 3,157 females) were included in the analysis (Figure 1 ).
Outcomes
Patients with newly diagnosed stroke, acute myocardial infarction (AMI), sudden cardiac and unexpected death (SCUD), or heart failure were registered through December 2012. Registration was initially performed by attending physicians at each hospital. To ensure the complete capture of all registrations, investigators consisting of physicians and trained research nurses visited and reviewed medical charts and/or discharge summaries at referral hospitals within the study area. Dates of death and relocation from the study area were annually or biannually confirmed by investigators who reviewed population registration sheets at each local government office. People who were known to be alive at the end of the follow-up and those who had moved away from the study area were treated as censored cases.
The endpoint of the study was a composite cardiovascular outcome comprising stroke, AMI, SCUD, and heart failure. Stroke was defined on the basis of symptoms (sudden onset of a focal neurological deficit of 24-hour duration) and brain imaging including brain computed tomography or magnetic resonance imaging, and was identified by local stroke registry data. 13 Heart failure was defined according to the Framingham criteria 14 and identified by investigators from medical records at all general hospitals located within the study area. AMI was defined according to the MONItoring of trends and determinants in CArdiovascular Disease (MONICA) criteria. 15 From hospital registration survey data, cases with acute AMI were identified if they met the MONICA diagnostic AMI criteria corresponding to either definite AMI, possible coronary death, or unclassifiable SCUD. According to the WHO criteria for sudden death, SCUD was defined as sudden unexpected death within 24 hours of having been observed alive and symptom-free. 16 SCUD was identified by reviewing death certificates filed at referral hospitals and/or public health centers in the study area and was determined by a committee consisting of cardiologists, neurologists, and epidemiologists. The study was approved by our institutional ethics committee.
Measurements
The body mass index (BMI) was calculated by dividing the weight (in kilograms) by the square of the height (in meters). Participants completed a self-reported questionnaire to document their medical history including current medications and lifestyle factors such as a smoking habit. BP was measured twice using an automatic digital sphygmomanometer after at least 5 minutes of rest in a sitting position, and the average of these 2 values was used for the analysis. Blood samples were drawn from an antecubital vein and collected into vacuum tubes containing a serum separator gel. Tubes were stored immediately after sampling in an icebox and transported to the laboratory within 8 hours after collection. The estimated glomerular filtration rate was calculated using CKD-EPI equations modified by a Japanese coefficient. 17 
Risk factor definition
Diabetes mellitus was defined as a random blood glucose level ≥200 mg/dl, a fasting blood glucose level ≥126 mg/dl, a glycosylated hemoglobin (hemoglobin A1c, NGSP equivalent value) ≥6.5%, and/or current anti-diabetic therapy. Dyslipidemia was defined as total cholesterol levels ≥240 mg/dl, high-density lipoprotein cholesterol levels <40 mg/dl, and/ or current lipid lowering therapy. The high BP category was defined as systolic BP ≥120 mm Hg but <140 mm Hg and/ or diastolic BP ≥80 mm Hg but <90 mm Hg, according to the criteria of prehypertension introduced by the Seventh Joint National Committee on the Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC-7) in 2003. 18 A smoking habit was defined as currently smoking. As the classical risk index, the Framingham 10-year risk score (FRS) was calculated on the basis of the categorical values for age, total cholesterol, high-density lipoprotein cholesterol, systolic BP, treatment for hypertension, smoking status, and diabetes status. 19 
Electrocardiography
At the baseline examination, the study participants underwent standard supine 12-lead ECG after a minimum 5-minute rest period. Blinded to the participants' clinical data, 2 trained research nurses assessed the participants' ECG parameters. The Sokolow-Lyon (SL) voltage (SV1 + RV5/V6) and Cornell voltage (CV: SV3 + RaVL) were measured on 3 consecutive heartbeats. The QRS duration on 3 consecutive heartbeats were measured from lead II (or lead I, III, or aVF when the measurement of QRS duration was difficult from lead II). The Cornell voltage product (CP) was calculated as the CV (+ 0.8 mV in women) × QRS duration. From the average of these measured values, ECG-LVH was defined according to the following criteria: the SL voltage ≥3.8 mV; the CV >2.8 mV for men and >2.0 mV for women; the CP ≥244 mV × ms. 20, 21 The intraclass and interclass correlation coefficients for the measured ECG parameters were analyzed with the 
Statistical analyses
The baseline data were presented as the mean ± SD or percentage. The comparison of continuous and categorical variables at baseline were performed by a 1-way analysis of variance and the χ 2 test, respectively, between the presence and absence of ECG-LVH by any criteria of the SL voltage, CV, and CP.
The onset time of the first event was considered the primary endpoint. The multivariate regression analysis was adjusted as follows: model 1: age, sex; model 2: systolic BP, BMI, estimated glomerular filtration rate, diabetes mellitus (yes or no), dyslipidemia (yes or no), smoking habit (yes or no) in addition to model 1. The Cox's proportional hazard regression analysis was used to calculate hazard ratios (HRs) and corresponding 95% confidence intervals for composite CVE in the presence of ECG-LVH. In addition to the main analyses, the subgroup analyses were conducted according to age (above or below 70 years), sex, and the presence or absence of any of obesity defined as BMI ≥25 (kg/m 2 ), dyslipidemia, or diabetes mellitus, and the high BP category. To evaluate an interaction effect between baseline ECG status and the above risk factors, the P value of an interaction term from the Cox's proportional hazards regression model with the outcome of the subgroup of interest and baseline ECG status were calculated. Furthermore, to estimate the CVE risk attributed to presence of ECG-LVH, the populationattributable fraction was calculated as Pe × (HR -1)/HR, in which Pe is the proportion of incident cases in each risk category and HR is the full multiple-adjusted HR. We tested the assumption of linearity for the Cox model by modeling the outcome by a time by baseline ECG-LVH status through visual inspection and found no violation of proportional hazards.
To determine the improvement in the model discrimination with the inclusion of ECG-LVH parameters into the FRS, we calculated the net reclassification improvement and the integrated discrimination improvement. The net reclassification improvement is centered on reclassification tables constructed separately for individuals with or without an outcome endpoint and quantifies the correct movement: upward for events and downward for nonevents. 22 The integrated discrimination improvement represents the mean difference in predicted probabilities between models with and without the new marker. 22 All of the data were analyzed with the SPSS statistical software program (version 11.0) or R software program (version 3.1.3; available from https:// www.r-project.org). P <0.05 was considered to be statistically significant. Table 1 shows the characteristics of the study participants which are categorized according to the presence or absence of ECG-LVH by any criteria of the SL voltage, CV, and CP. In participants with ECG-LVH, compared to those without ECG-LVH, the age, systolic and diastolic BPs, FRS, and the prevalence of male sex and the high BP category were likely to be higher, whereas the BMI, total cholesterol, estimated glomerular filtration rate, and the prevalence of dyslipidemia were likely to be lower. The prevalence of LVH by the criteria of the SL voltage, CV, and CP were 581 (11.7%), 93 (1.9%), and 94 (1.9%), respectively ( Table 2) .
RESULTS
During the average 9.8 ± 2.0 years of follow-up, 267 individuals (5.4%) had their first CVEs, comprising 188 events of stroke, 49 events of AMI/SCUD, and 30 events of heart failure. Table 2 shows the relationship between ECG-LVH and the risk of CVE after the adjustment for potential confounding factors in the Cox models. The HR for the incidence of CVE after full adjustment significantly increased in ECG-LVH by Abbreviations: CI, confidence interval; ECG-LVH, left ventricular hypertrophy on 12-lead electrocardiography; HR, hazard ratio; PAR, population-attributable fraction.
a HR in the Cox's proportional hazards regression model including age, sex, body mass index, systolic blood pressure, estimated glomerular filtration rate, diabetes mellitus (yes or no), dyslipidemia (yes or no), smoking status (yes or no).
b The population-attributable fraction from the presence of ECG-LVH.
all criteria (HR = 1.72 in the SL voltage, 2.23 in the CV, 2.31 in the CP, 1.77 in any LVH criteria, all P < 0.001) compared to no ECG-LVH. The relationship between ECG-LVH by any criteria and the incidence of CVE was more evident in women than men (P = 0.049 for the sex-LVH interaction term, Figure 2 ). Moreover, this relationship was significant even in individuals without any of obesity, dyslipidemia, and diabetes mellitus and those without the high BP category (Figure 2 ). The population-attributable fraction to incident CVE was 9.7%, 3.3%, 3.0%, and 11.6% from the presence of each criteria of the SL voltage, CV, and CP and any ECG-LVH criteria, respectively (Table 2) . Table 3 shows the reclassification improvement for the CVE risk prediction model by the inclusion of ECG-LVH parameters into the FRS model. The net reclassification improvement and integrated discrimination improvement were 0.217 and 0.007 for the inclusion of SL voltage, 0.191 and 0.006 for the inclusion of CV, and 0.174 and 0.007 for the inclusion of CP, respectively, all of which were statistically significant (Table 3) .
DISCUSSION
The key finding in this study is that in the absence of hypertension, the relationship between ECG-LVH and the risk of CVE was significant independent of age, sex, systolic BP levels, and the status of obesity, dyslipidemia, and diabetes mellitus at baseline. The additional important finding is that ECG-LVH parameters improved the accuracy of reclassification in the traditional risk prediction model.
LVH is acknowledged as a measure of hypertensive organ damage and a predictor for future CVE in hypertensive individuals. 2, 3 Also in the general population, it has been reported that there is a relationship between ECG-LVH and the risk of incident CVE. [4] [5] [6] This relationship might be mediated in part through hypertensive vascular atherosclerosis. In the health 2000 survey among the Finnish adult population, ECG-LVH was associated with higher risk of incident CVE in hypertensive individuals but not those without hypertension. 2 In a Japanese normotensive cohort, ECG-LVH by the CP criteria was associated with the incidence of stroke, but that by the SL voltage criteria was not. 23 However, in the present non-hypertensive participants, ECG-LVH by all criteria of the SL voltage, CV, and CP were related to the increased risk of CVE. The reasons for this discrepancy are unclear but may involve differences in participants' characteristics and the measured outcomes as the endpoint, as the incidence of stroke, compared with that of coronary heart disease, was much higher in the present Japanese population in contrast to western populations.
The heart is a key target organ of high BP, and the myocardium responds to increased afterload by developing LVH. However, left ventricular mass is also determined by factors other than arterial BP, such as genetic factors, 24 insulin resistance, 25 obesity, 26 and alcohol intake, 27 independent of BP. In the study targeting non-hypertensive patients, the independent indicators of LVH were fasting plasma glucose, hemoglobin A1c, triglycerides, high-density lipoprotein cholesterol, and BMI. 10 However, these factors may not be able to explain our findings sufficiently, as our study participants without any of obesity, dyslipidemia, or diabetes also had the ECG-LVH-related risk of CVE (figure). In the present study, the proportion of men tended to be higher in the participants with ECG-LVH compared with those without ECG-LVH. This finding was unlikely to affect the ECG-LVH-related risk of CVE, because its risk was rather more evident in women, which was consistent with the previous population-based cohort study. 5 Furthermore, our study included the individuals with the high BP category of systolic BP from 120 to 139 mm Hg and/or diastolic BP from 80 to 89 mm Hg which has been reported to be associated with alterations in cardiac morphology and functions 28 and the increased risk of future CVE. 29 However, in our study, this BP category was unlikely to explain the mechanism of relationship between ECG-LVH and the risk of CVE sufficiently, as its relationship was also significant in individuals without the high BP category (Figure 2 ). On the other hand, day-by-day BP variability by home measurements, independent of the average level of systolic BP at home, has been shown to be associated with the risk of cardiovascular mortality. 30 Additionally, in a general population without hypertension, LVH defined by the SL voltage or CP has been reported to be closely associated with future incidence of hypertension and correlated with increased BP. 11 This study suggests that transient (but frequent) increases in the BP and cardiac output that precede the development of hypertension cause LVH. Therefore, an increase in BP variability or transient BP elevation, unlikely to be identified as having abnormal high BP or hypertension in clinical practice, may account for the relationship between ECG-LVH and CVE incidence in the non-hypertensive subjects. In addition, it is possible that ECG-LVH, in part, represented structural heart disease such as valvular heart disease in our study in which average age was relatively high, as the prevalence of valvular disease increases markedly in the elderly population. 31, 32 The present study showed that ECG-LVH parameters improved the prediction of CVE risk beyond the traditional risk model based on the Framingham 10-year risk equation. In particular, ECG-LVH is likely to have superior utility to down-classify participants with higher risk profiles on the traditional model but who did not develop CVE (Table 2) . In a population-based cohort study in which hypertensives were included as a target, there was no reclassification improvement for the CVE prediction based on ECG-LVH in contrast to our finding. 6 This discrepancy may derive from the fact that our study participants did not have hypertension and were at the low or moderate risk category on the FRS model (average FRS at baseline: 12.6 point in men, 8.0 point in women). Hence, less presence of confounding traditional cardiovascular risk factors might lead to enhance the accuracy of ECG-LVH on the prediction of future CVE risk in the present study.
Our study had several limitations. First, in non-hypertensive participants, the rate of ECG-LVH by any criteria was 13.2% at baseline and, in particular, the rate of LVH under the SL voltage criteria was higher (11.7%) than that reported in the previous study. 2, 23 This result may derive from the fact that the average age was higher and the average BMI was lower in the present study, as the prevalence of LVH increases with age 33 and the accuracy of the SL voltage criteria is influenced by body mass. 34 Second, the present study recorded ECG and identified the clinical data and prescribed drugs such as antihypertensive agents only at baseline, although the changes in clinical data and the induction of medical treatment during follow-up may have affected the outcomes. Third, outpatients with no hospital admission were not registered in the present study, even if they developed CVE. This raises the possibility that the CVE cases without hospital admission, such as mild cases of heart failure, were not captured. Finally, in the present study conducted in a Japanese population, the cumulative incidence of stroke was much higher than that of AMI/SCUD (3.8% vs. 1.0%), consistent with reports from the previous Japanese epidemiological studies. 35, 36 Therefore, our results may not be simply extrapolated to populations of other races/ethnicities.
In conclusion, in the absence of hypertension, ECG-LVH is associated with an increased risk of incident CVE independent of age, sex, systolic BP levels, and the status of obesity, dyslipidemia, and diabetes mellitus. Furthermore, ECG-LVH parameters provide an additional prognostic value to the assessment of CVE risk based on established risk factors. These results suggest that applying ECG-LVH criteria can help appropriately identify the increased risk of CVE among a great number of non-hypertensive people. 
